You need to be logged in to see the full monograph.


Date of issue: May 2020, Version: 3

bumps logo
A corresponding patient information leaflet on PATERNAL USE OF METHOTREXATE is available.

Methotrexate (MTX) is a folic acid antagonist used in the treatment of some cancers, as well as rheumatoid arthritis and severe psoriasis.

Hypothetical concerns have been raised that due to its effects on DNA replication, use of MTX in males could cause genetic abnormalities in sperm. This could potentially affect offspring conceived during ongoing use or within one sperm cycle (~74 days) of cessation. However, the available pregnancy outcome data relating to offspring conceived following periconceptual paternal MTX use do not raise concerns of increased risks of congenital malformation or other adverse outcomes. Available data are limited to around 400 exposures and ongoing data capture is therefore important.

The manufacturers of MTX advise that couples, where the male partner is undergoing or has recently completed MTX treatment, use reliable contraception and wait six months after cessation of treatment before attempting conception. Since there is no conclusive evidence of adverse fetal effects relating to paternal use, UKTIS recommends that where a couple wishes to attempt conception and the male partner’s condition is well-controlled with MTX, an assessment and discussion of the potential benefits and risks of continuing paternal treatment vs. discontinuation should be undertaken. The risks to the fetus are theoretical rather than established.

Paternal MTX use at the time of conception is not an indication for additional fetal monitoring. However, other risk factors may be present in individual cases which may independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from to ensure you are using the most up-to-date version.